This article was originally published in The Tan Sheet
FTC votes 5-0 Jan. 26 to make final its consent order approving merger of Glaxo Wellcome and SmithKline Beecham. Commission also votes 5-0 to close its investigation into the effects merger would have on the smoking cessation market; combined company will market Rx drug Zyban (bupropion) and OTC Nicoderm CQ transdermal patch and Nicorette gum. In a Jan. 23 letter to each firm's counsel, FTC notes closure of the smoking cessation investigation "should not be construed as a determination that a violation may not have occurred...The commission reserves the right to take such further action as the public interest may require"
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC